Management of chronic viral hepatitis

American Family Physician

Volumn 55, Issue 8, 1997, Pages 2749-2756

  Vail, Belinda A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; FAMCICLOVIR; LAMIVUDINE; RIBAVIRIN;

ACTIVE IMMUNIZATION; ALOPECIA; ANXIETY NEUROSIS; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; DELTA AGENT HEPATITIS; DEPRESSION; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION PREVENTION; INFECTION RISK; PREVALENCE; RASH; SEXUAL TRANSMISSION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ALGORITHMS; CHRONIC DISEASE; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; HEPATITIS B; HEPATITIS C; HEPATITIS D; HEPATITIS, VIRAL, HUMAN; HUMANS;

EID: 0031010743     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bowden DS, Moaven LD, Locarnini SA. New hepatitis viruses: are there enough letters in the alphabet? Med J Aust 1996;164:87-9.
2. Alter MJ, Gallagher M, Morris TT, Moyer LA, Meeks EL, Krawczynski K, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinal counties viral Hepatitis Study Team. N Engl J Med 1997;336:741-6.
3. Alter MJ, Nakatsuji Y, Melpolder J, Wages I, Wesley R, Shih JW, et al. The incidence of transfusion-associated hepatitis G virus infection and its relationship to liver disease. N Engl J Med 1997;336:747-54.
4. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40 (RR-13):1-25.
5. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-55.
6. Sjogren MH. Serologic diagnosis of viral hepatitis. Gastroenterol Clin North Am 1994;23:457-77.
7. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
8. Marsano LS, Greenberg RN, Kirkpatrick RB, Zetterman RK, Christiansen A, Smith DJ, et al. Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults. Am J Gastroenterol 1996;91:111-5.
9. Hoofnagle JH, Lau D. Chronic viral hepatitis - benefits of current therapies [Editorial]. N Engl J Med 1996;334:1470-1.
10. Perrillo RP, Mason AL. Therapy for hepatitis B virus infection. Gastroenterol Clin North Am 1994;23:581-601.
11. Huang EJ, Wright TL, Lake JR, Combs C, Ferrell LD. Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation. Hepatology 1996;23:396-404.
12. Cantell K. Development of antiviral therapy with alpha interferon: promises, false hopes, and accomplishments. Ann Med 1995;27:23-8.
13. Colquhoun SD. Hepatitis C. A clinical update. Arch Surg 1996;131:18-23.
14. Zein NN, Persing DH. Hepatitis C genotypes: current trends and future implications. Mayo Clin Proc 1996:71:458-62.
15. Seymour CA. Screening asymptomatic people at high risk for hepatitis C. The case for. BMJ 1996; 312:1347-8.
16. Allison MC, Mills PR. Screening asymptomatic people at high risk for hepatitis C. The case against. BMJ 1996;312:1349-50.
17. Dusheiko GM, Khakoo S, Soni P, Greffier L. A rational approach to the management of hepatitis C infection. BMJ 1996;312:357-64.
18. Floreani A, Paternoster D, Zappala F, Cusinato R, Bombi G, Grella P, et al. Hepatitis C virus infection in pregnancy. Br J Obstet Gynaecol 1996;103:325-9.
19. Wong V, Wreghitt TG, Alexander GJ. Prospective study of hepatitis B vaccination in patients with chronic hepatitis C. BMJ 1996;312:1336-7.
20. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996;173:822-8.
21. Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B. High-dose interferon-alpha 2b for retreatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Dig Dis Sci 1996;41:149-54.
22. Jenkins PJ, Cromie SL, Bowden DS, Finch CF, Dudley FJ. Chronic hepatitis C and interferon alfa therapy: predictors of long term response. Med J Aust 1996;164:150-2.
23. Kao JH, Lai MY, Chen PJ, Hwang LH, Chen W, Chen DS. Clinical significance of serum hepatitis C virus titers in patients with chronic type C hepatitis. Am J Gastroenterol 1996;91:506-10.
24. Hanley JP, Jarvis LM, Andrews J, Dennis R, Hayes PC, Piris J, et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs - influence of virus load, genotype, and liver pathology on response. Blood 1996;87:1704-9.
25. Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, Noguchi O, et al. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci 1996;41:989-94.
26. Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996;110:291-5.
27. Vento S, Concia E, Ferraro T. Lack of sustained efficacy of interferon in patients with chronic hepatitis C [Letter]. N Engl J Med 1996;334:1479-80.
28. Cattral MS, Krajden M, Wanless IR, Rezig M, Cameron R, Greig PD, et al. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 1996;61:1483-8.